Lytix Biopharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Oystein Rekdal
Chief executive officer
NOK 4.8m
Total compensation
| CEO salary percentage | 72.7% |
| CEO tenure | 22yrs |
| CEO ownership | 0.3% |
| Management average tenure | 6.3yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Aug 31
We're A Little Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Mar 02We're Keeping An Eye On Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Oct 04We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Jun 21Companies Like Lytix Biopharma (OB:LYTIX) Are In A Position To Invest In Growth
Jan 11We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Jul 16We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Jan 25We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Sep 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -NOK 81m |
| Jun 30 2024 | n/a | n/a | -NOK 76m |
| Mar 31 2024 | n/a | n/a | -NOK 86m |
| Dec 31 2023 | NOK 5m | NOK 3m | -NOK 88m |
| Sep 30 2023 | n/a | n/a | -NOK 99m |
| Jun 30 2023 | n/a | n/a | -NOK 91m |
| Mar 31 2023 | n/a | n/a | -NOK 61m |
| Dec 31 2022 | NOK 4m | NOK 4m | -NOK 56m |
| Sep 30 2022 | n/a | n/a | -NOK 43m |
| Jun 30 2022 | n/a | n/a | -NOK 51m |
| Mar 31 2022 | n/a | n/a | -NOK 63m |
| Dec 31 2021 | NOK 8m | NOK 7m | -NOK 48m |
| Sep 30 2021 | n/a | n/a | -NOK 44m |
| Jun 30 2021 | n/a | n/a | -NOK 40m |
| Mar 31 2021 | n/a | n/a | -NOK 35m |
| Dec 31 2020 | NOK 7m | NOK 4m | -NOK 42m |
| Dec 31 2019 | NOK 2m | NOK 2m | -NOK 33m |
| Dec 31 2018 | NOK 2m | NOK 2m | -NOK 62m |
Compensation vs Market: Oystein's total compensation ($USD418.12K) is above average for companies of similar size in the Norwegian market ($USD283.92K).
Compensation vs Earnings: Oystein's compensation has increased whilst the company is unprofitable.
CEO
Oystein Rekdal
22yrs
Tenure
NOK 4,765,000
Compensation
Dr. Oystein Rekdal, Ph.D. co-founded Lytix Biopharma AS in 2003 and serves as its Chief Executive Officer since September 11, 2019. Dr. Rekdal was Chief Scientific Officer of Lytix Biopharma AS since April...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & CEO | 22yrs | NOK 4.77m | 0.32% NOK 917.8k | |
| Chief Financial Officer | 6.3yrs | no data | 0.056% NOK 162.8k | |
| Chief Scientific Officer | 5.1yrs | no data | 0.025% NOK 73.9k | |
| Head of IR & Communication Manager | no data | no data | no data | |
| Head of Clinical Operations | no data | no data | no data |
6.3yrs
Average Tenure
Experienced Management: LYTIX's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Non-Executive Independent Director | 3.6yrs | NOK 331.00k | 0.027% NOK 79.1k | |
| Member of Scientific Advisory Board | 5.6yrs | no data | no data | |
| Non-Executive Independent Director | 3.6yrs | NOK 331.00k | no data | |
| Non-Executive Independent Director | 3.6yrs | NOK 331.00k | no data | |
| Chairperson | 1.8yrs | NOK 91.00k | no data | |
| Member of Scientific Advisory Board | 5.6yrs | no data | no data | |
| Director | 3.6yrs | NOK 331.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Independent Director | 3.6yrs | NOK 331.00k | 0.0086% NOK 24.9k | |
| Member of Supervisory Advisory Board | less than a year | no data | no data |
3.6yrs
Average Tenure
62yo
Average Age
Experienced Board: LYTIX's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 22:21 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lytix Biopharma AS is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carl Ramanius | Redeye |